Precipio, Inc. (PRPO)
$1.16
+0.04 (+3.57%)
Rating:
Recommendation:
Buy
| Symbol | PRPO |
|---|---|
| Price | $1.16 |
| Beta | 2.281 |
| Volume Avg. | 0.27M |
| Market Cap | 26.342M |
| Shares () | - |
| 52 Week Range | 0.91-4.65 |
| 1y Target Est | - |
| DCF Unlevered | PRPO DCF -> | |
|---|---|---|
| DCF Levered | PRPO LDCF -> | |
| ROE | -46.73% | Strong Sell |
| ROA | -41.71% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 25.75% | Neutral |
| P/E | - | |
| P/B | 1.19 | Strong Buy |
Latest PRPO news
About
Download (Excel)Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.